Mode
Text Size
Log in / Sign up
N/A N=53 Randomized Triple-blind Treatment

Effects of Device-assisted Practice of ADL on Arm/Hand Recovery in Individuals With Moderate to Severe Stroke

Stroke

Enrolled (actual)
53
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcome: Primary: Box and Blocks Test (BBT) — 5.7; 8.8 blocks

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
ReIn-Hand (Device); Robot (Device)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Northwestern University
Primary completion
Dec 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Box and Blocks Test (BBT)
5.7; 8.8
SECONDARY
Upper Extremity Fugl-Meyer Assessment Score
23.0; 24.3
SECONDARY
Chedoke McMaster Stroke Assessment (CMSA) Hand Subscale
3.4; 3.4
SECONDARY
Action Research Arm Test (ARAT)
13.8; 17.6
SECONDARY
Kinaesthesia Subscale of Nottingham Sensory Assessment
8.42; 9.72
SECONDARY
Cutaneous Sensory Touch Threshold Using Semmes-Weinstein Monofilaments
4.51; 4.59; 3.39; 3.57
SECONDARY
Motor Activity Log (MAL)
0.84; 0.94; 0.86; 1.02
SECONDARY
Stroke Impact Scale (SIS) Stroke Recovery Question
61; 62
SECONDARY
Stereognosis Subscale of Nottingham Sensory Assessment
12.1; 14.5
SECONDARY
Quantitative Measure of Hand Closing Force (QMHC)
69.86; 77.02; 18.06; 22.61
SECONDARY
Fractional Anisotropy (FA) of Bilateral Cortico-fugal Tracts
0.4140; 0.4181; 0.3700; 0.3677
SECONDARY
Hand Pentagon Area (HPA) While Opening With or Without Lifting
21.66; 19.42; 19.43; 15.77
SECONDARY
Global Rating of Change (GROC)
3.15; 4.25

Summary

A large number of post-stroke survivors cannot functionally use their paretic upper extremity (UE). This study therefore investigates effects of device-assisted practice of activities of daily living (ADL) in a close-to-normal pattern on UE motor recovery in individuals with moderate to severe stroke by measuring intervention-induced changes in clinical outcomes, UE kinematics, and functional and morphologic neuroplasticity. Positive findings may impact current clinical practice by pushing towards implementing device-assisted practice of ADLs and have the potential to benefit a large population.

Eligibility Criteria

Inclusion Criteria

  • Age between 21-80
  • Paresis confined to one side, with substantial motor impairment of the upper limb and some residual voluntary movement (Upper Extremity Fugl-Meyer Assessment score in the range of 10-40/66, Chedoke McMaster Stroke Assessment - Stage of the hand section score =23

Exclusion Criteria

  • Motor or sensory impairment in the non-affected limb
  • Any brainstem and/or cerebellar lesion
  • Severe concurrent medical problems (e.g. cardiorespiratory impairment, uncontrolled hypertension, inflammatory joint disease)
  • History of neurologic disorder other than stroke (Parkinson's Disease, Acute Lateral Sclerosis, Multiple Sclerosis, Traumatic Brain Injury, peripheral neuropathy, Amyotrophic lateral sclerosis, spinal cord injury, Dementia)
  • Any acute or chronic painful condition in the upper extremities or spine, indicated by a score ≥5 on a 10-point visual analog scale
  • Using cardiac pacemaker, implanted cardioverter defibrillator, neurostimulation system inside the brain or spinal cord, bone growth box fusion stimulation
  • Seizure in the last 6 months
  • Severe upper extremity sensory impairment indicated by absent sensation on the tactile sensation subscale (light touch and pressure items) of the Revised Nottingham Assessment of Somato-Sensations (score<4)
  • Chemo denervation: botulinum toxin, dysport, or Myobloc or phenol block injection to any portion of the paretic UE within the last 6 months, or phenol/alcohol injections <12 months before participation
  • Unable to passively attain 90 degrees of shoulder flexion and abduction, measured using a goniometer based on adapted methods
  • Flexion contractures larger than 45 degrees in the elbow, wrist, metacarpophalangeal joints (MCP) and interphalangeal joints (IP) of thumb and index finger
  • Pregnant or planning to become pregnant
  • Participating in any experimental rehabilitation or drug studies
  • Inability to attend intervention sessions 3 times a week during 8 weeks, as well as to assessments/evaluations and follow up
  • Upper extremity musculoskeletal impairment limiting function prior to stroke
  • Currently using oxygen
  • Upper limb amputation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04077073). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search